NCT02224625

Brief Summary

Evaluating the irritation properties of CHG cloth. Some Subjects will also have the product applied to see if they become sensitized to repeated applications.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
249

participants targeted

Target at P50-P75 for phase_3 surgery

Timeline
Completed

Started Aug 2014

Shorter than P25 for phase_3 surgery

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

August 20, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 25, 2014

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
12 months until next milestone

Results Posted

Study results publicly available

May 30, 2016

Completed
Last Updated

March 9, 2017

Status Verified

March 1, 2016

Enrollment Period

10 months

First QC Date

August 20, 2014

Results QC Date

February 5, 2016

Last Update Submit

January 27, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • Grading Scale for Visual Evaluation of Skin Condition

    Irritation: 21 days of patching (total). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. Sensitization: 35 days (21 days of patching followed by 14 days rest and subsequent patch). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. SLS was not tested. Grade 0 = No irritation Grade 1 = Minimal erythema Grade 2 = Definite erythema Grade 3 = Erythema and papules Grade 4 = Edema Grade 5 = Erythema, edema and papules Grade 6 = Vesicular eruption Grade 7 = Strong reaction spreading

    21 Days for Irritation (N=39). 35 Days for Sensitization (N=249)

Study Arms (5)

2% CHG Cloth

EXPERIMENTAL

Chlorhexidine Gluconate 2%

Drug: 2% CHG Cloth solution

Vehicle Cloth

PLACEBO COMPARATOR

Excipients on cloth

Device: Vehicle Cloth

DynaHex (2% CHG)

ACTIVE COMPARATOR

Chlorhexidine Gluconate 2% solution

Drug: Active Comparator

Saline

SHAM COMPARATOR

0.9% sodium chloride

Other: Saline

Sodium Lauryl Sulfate (SLS)

ACTIVE COMPARATOR

Sodium lauryl sulfate to produce mild irritation as a positive control

Other: SLS

Interventions

Investigational CHG

Also known as: Chlorhexidine Gluconate
2% CHG Cloth

Excipients from CHG cloth only

Also known as: Control
Vehicle Cloth

Active comparator

Also known as: DynaHex-2
DynaHex (2% CHG)
SalineOTHER

Negative control

Saline
SLSOTHER

Provides a slight irritation for a positive control

Also known as: Sodium Lauryl Sulfate
Sodium Lauryl Sulfate (SLS)

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Free of skin disorders
  • Signed consent

You may not qualify if:

  • Allergies to latex
  • Topical or systemic steroids, antihistamines, antiinflammatory agents 7 days prior or during testing
  • severe illness
  • Pregnant (females)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

BioScience Laboratories

Butte, Montana, 59701, United States

Location

MeSH Terms

Interventions

chlorhexidine gluconateSodium ChlorideSodium Dodecyl Sulfate

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsDodecanolFatty AlcoholsAlcoholsOrganic ChemicalsAlkanesulfonatesAlkanesulfonic AcidsSulfonic AcidsSulfur AcidsSulfur CompoundsLipids

Results Point of Contact

Title
C Beausoleil
Organization
Bioscience Labs

Study Officials

  • J Pullman, MD

    BioScience Laboratories

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 20, 2014

First Posted

August 25, 2014

Study Start

August 1, 2014

Primary Completion

June 1, 2015

Study Completion

June 1, 2015

Last Updated

March 9, 2017

Results First Posted

May 30, 2016

Record last verified: 2016-03

Data Sharing

IPD Sharing
Will share

Data to be shared with FDA

Locations